Dapagliflozin and linagliptin combination therapy improves time in range and reverses hepatic steatosis in patients with type 2 diabetes and hypertension - Report - MDSpire

Dapagliflozin and linagliptin combination therapy improves time in range and reverses hepatic steatosis in patients with type 2 diabetes and hypertension

  • By

  • WenXia Li

  • RuRan Li

  • ShanShan Li

  • Zhen Li

  • JingSu Ma

  • Fei Wu

  • ChaoQin Chen

  • May 11, 2026

  • 0 min

Share

Clinical Report: Dapagliflozin and Linagliptin Improve Glycemic Control

Overview

The combination of dapagliflozin and linagliptin significantly enhances glycemic control and reduces liver fat accumulation in individuals with type 2 diabetes and hypertension. This study demonstrates superior time in range and improved hepatorenal function compared to monotherapy.

Background

The prevalence of type 2 diabetes mellitus (T2DM) is rising globally, with a significant proportion of patients also suffering from hypertension. This comorbidity increases the risk of vascular complications, necessitating effective treatment strategies. Understanding the benefits of combination therapies can optimize management in this high-risk population.

Data Highlights

OutcomeCombination TherapyMonotherapyControl
Time in Range (TIR)94.86 ± 3.65%~80%81.44%
HbA1c5.52%Not specifiedNot specified
Systolic Blood Pressure124 mmHgNot specifiedNot specified
Triglycerides0.72 mmol/LNot specifiedNot specified
ALT9.74 U/LNot specifiedNot specified
UACR7.36 mg/gNot specifiedNot specified
eGFR122.41 mL/min/1.73m²Not specifiedNot specified

Key Findings

  • Combination therapy achieved a TIR of 94.86 ± 3.65%, significantly higher than monotherapies and control.
  • HbA1c levels decreased to 5.52% with combination therapy.
  • Systolic blood pressure reduced to 124 mmHg in the combination group.
  • Combination therapy resulted in lower triglycerides (0.72 mmol/L) and ALT (9.74 U/L).
  • Improvement in UACR to 7.36 mg/g and eGFR to 122.41 mL/min/1.73m² was observed with combination therapy.

Clinical Implications

The findings support the use of dapagliflozin and linagliptin combination therapy as an effective strategy for managing T2DM in patients with hypertension. Clinicians should consider this combination to enhance glycemic control and protect against organ damage in this population.

Conclusion

Dapagliflozin and linagliptin combination therapy offers significant benefits in glycemic stability and organ protection for individuals with T2DM and hypertension, warranting its consideration in treatment plans.

Related Resources & Content

  1. New England Journal of Medicine, 2023 -- Dapagliflozin Reduces Cardiovascular Death in Patients with Heart Failure and Preserved Ejection Fraction
  2. conexiant, 2023 -- FDA Approves First Generic Versions of FARXIGA
  3. conexiant, 2023 -- Empagliflozin Tested in Real-World Data
  4. Frontiers in Endocrinology, 2023 -- Clinical efficacy, safety, and predictors of treatment response to SGLT2 versus DPP-4 inhibitors in type 2 diabetes
  5. Table 1. Glycemic Target Recommendations from the... - Endotext - NCBI Bookshelf
  6. American Diabetes Association, 2023 -- Statement on Liver Disease in Diabetes
  7. Efficacy and safety of a fixed-dose combination of dapagliflozin and linagliptin, 2023
  8. Table 1. [Glycemic Target Recommendations from the...]. - Endotext - NCBI Bookshelf
  9. The American Diabetes Association Announces Statement on Liver Disease in Diabetes | American Diabetes Association
  10. Efficacy and safety of a fixed-dose combination of dapagliflozin and linagliptin (AJU-A51) in patients with type 2 diabetes mellitus: A multicentre, randomized, double-blind, parallel-group, placebo-controlled phase III study - PubMed

Original Source(s)

Dapagliflozin and linagliptin combination therapy improves time in range and reverses hepatic steatosis in patients with type 2 diabetes and hypertension

  • by WenXia Li, RuRan Li, ShanShan Li, Zhen Li, JingSu Ma, Fei Wu, ChaoQin Chen

  • May 11, 2026

Related Content

Digitalis Reduces HF Events but Not Mortality

Meta-analysis of randomized trials found fewer worsening heart failure events among patients with reduced or mildly reduced ejection fraction.

Evidence-based clinical practice guidelines for metabolic dysfunction-associated steatotic liver disease (MASLD) 2026

Invasive NSTEMI Strategy Shows No Benefit in Frail Patients

Frailty severity may identify older patients least likely to benefit—and potentially at higher risk—with invasive management.